Sjogren’s syndrome: models of pathogenesis and treatment targets

Bibliography

• DERK CT, VIVINO FB: A primary care approach to Sjogren's syndrome: helping patients cope with sicca symptoms, extraglandular manifestations. Postgrad. Med. (2004) 116(3):49–65.
   PubMed Web of Science ®Google Scholar
• SJOGREN H: Zur Kenntnis der keratoconjuctivitis sicca (keratitis filiformid bei hypofunktion der tranendrusen). Acta. Ophthalmol (1933) 11 (Suppl. 2):1–9.
   Google Scholar
• TALAL N: Recent developments in the immunology of Sjogren's syndrome (autoimmune exocrinopathy). Scand. Rheumatol (1986) 61:(Suppl.):76–82.
   Google Scholar
• SKOPOULI FN, MOUTSOPOULOS HM: Autoimmune epitheliitis: Sjogren's syndrome. Clin. Exp. Rheumatol (1994) 12 (Supp1.11):S9–11.
   Google Scholar
• DROSOS AA, ANDONOPOULOS AP, COSTOPOULOS JS et al.: Prevalence of prImary Sjogren's syndrome in an elderly population. Br. J. Rheumatol. (1988) 27(2):123–127.
   PubMedGoogle Scholar
• THOMAS E, HAY EM, HAJEER A et al: Sjogren's: a community-based study of prevalence and impact. Br. J. Rheumatol. (1998) 37(10):1069–1076.
   PubMedGoogle Scholar
• JONSONN R, HAGA HJ, GORDON TP: Current concepts on diagnosis, autoantibodies and therapy in Sjogren's syndrome. Scand. Rheumatol (2000) 29(6):341–348.
   PubMed Web of Science ®Google Scholar
• ANAYA JM, TALAL N: Sjogren's syndrome comes of age. Semin. Arthritis Rheum. (1999) 28(6):355–359.
   PubMed Web of Science ®Google Scholar
• TAPINOS NI, POLIHRONIS M, TZIOUFA AG et al.: Sjogren's syndrome: autoimmune epitheliitis. Adv. Exp. Med. Biol. (1999) 455:127–134.
   PubMed Web of Science ®Google Scholar
• GORDON TP, BOLSTAD M, RISCHMUELLER M et al: Autoantibodies in primary Sjogren's syndrome: new insights into mechanisms of autoantibody diversification and disease pathogenesis. Autoimmunity (2001) 34(2):123–132.
   PubMed Web of Science ®Google Scholar
• VITALI C, BOMBARDIERI S, JONSSON R et al.: Classification criteria for Sjogren's syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. Ann. Rheum. Dis. (2002) 61(0:554–548.
   PubMedGoogle Scholar
• MAINI RN: The relationship of Sjogren's syndrome to rheumatoid arthritis. In: Sjogren's syndrome: clinical and immunological aspects. Talal N, Moutsopoulos HM, Kassan SS (Eds), Springer Verlag, Berlin (1987):165–177.
   Google Scholar
• VENABLES PJ: Sjogren's syndrome. Best Pract. Res. Clin. Rheum. (2004) 18(3):313–329.
   PubMedGoogle Scholar
• CARSONS S: Sjogren' syndrome. In : Kelley's Textbook of Rheumatology 7th ed. Hariis ED (Ed.), Elsevier, Philadelphia, USA (2005):1105–1122.
   Google Scholar
• TURKCAPAR N, SAK SD, SAATCI M et al: Vasculitis and expression of vascular cell adhesion molecule-1, intercellular adhesion molecule-1, and E-selectin in salivary glands of patients with Sjogren's syndrome. J. Rheumatol (2005) 32(6):1063–1070.
   PubMed Web of Science ®Google Scholar
• AZIZ KE, MCCLUSKEY PJ, WAKEFIELD D: Expression of selectins (CD62 E,L,P) and cellular adhesion molecules in primary Sjogren's syndrome: questions to immunoregulation. Clin. Immunol Immunopathol (1996) 80:55–66.
   PubMedGoogle Scholar
• SAITO I, TERAUCHI K, SHIMUTA M et al: Expression of cell adhesion molecules in the salivary and lacrimal glands of Sjogren's syndrome. J. Clin. Lab. Anal. (1993) 7(3):180–187.
   PubMed Web of Science ®Google Scholar
• KAPSOGEORGOU EK, DIMITRIOU ID, ABU-HELU RF et al.: Activation of epithelial and myoepithelial cells in the salivary glands of patients with Sjogren's syndrome: high expression of intracellular adhesion molecule-1 (ICAM-1) in biopsy specimens and cultured cells. Clin. Exp. Immunol (2001)124:126–133.
   PubMed Web of Science ®Google Scholar
• TSUNAWAKI S, NAKAMURA S, OHYAMA Yet al.: Possible function of salivary gland epithelial cells as nonprofessional antigen-presenting cells in the development of Sjogren's syndrome. Rheumatol (2002) 29(9):1884–1896.
   Google Scholar
• MITSIAS DI, TZIOUFAS AG, VEIOPOULOU C et al: The TH1/TH2 cytokine balance changes with the progress of the immunopathological lesion of Sjogren's syndrome. Clin. Exp. Immunol. (2002) 128:562–568.
   PubMed Web of Science ®Google Scholar
• OXHOLM P, DANIELS TE, BENDTZEN K: Cytokine expression in labial salivary glands from patients with primary Sjogren's. Autoimmunity (1992) 12:185–191.
   PubMed Web of Science ®Google Scholar
• BOUMBA D, SKOPOULI FN, MOUTSOPOULOS HM: Cytokine mRNA expression in the labial salivary gland tissues from patients with primary Sjogren's syndrome. Br. J. Rheumatol (1995) 34:326–333.
   PubMedGoogle Scholar
• GAULT A, YANNI G, PITZALIS C et al: Cytokine and adhesion molecule expression in the minor salivary glands of patients with Sjogren's syndrome and chronic sialoadenitis. Ann. Rheum. Dis. (1995) 54(3):209–215.
   PubMed Web of Science ®Google Scholar
• OHYAMA Y, NAKAMURA S, MATSUZAKI G et al.: Cytokine messenger RNA expression in the labial salivary glands of patients with Sjogren's syndrome. Arthritis Rheum (1996) 39(8):1376–1384.
   PubMedGoogle Scholar
• SUN D, EMMERT-BUCK MR, FOX PC: Differential cytokine mRNA expression in human labial monor salivary glands in primary Sjogren's syndrome. Autoimmunity (1998) 28(3):125–137.
   PubMed Web of Science ®Google Scholar
• WU AJ, LAFRENIE RM, PARK C et al: Modulation of MMP-2 (gelatinase A) and MMP-9 (gelatinase B) by IFN-y in human salivary gland cell line. J. Cell. Physiol. (1997) 171(2):117–124.
   PubMed Web of Science ®Google Scholar
• HULKKOMEN J, PERTOOVARA M, ANTONEN J et al: Matrix metalloproteinase-9 (MMP-9) gene polymorphism and MMP-9 plasma levels in primary Sjogren's syndrome. Rheumatology (2004) 43:1476–1479.
   PubMed Web of Science ®Google Scholar
• GOICOVICH E, MOLINA C, PEREZ P et al: Enhanced degradation of proteins of the basal lamina and stroma by matrix metalloproteinases from the salivary glands of Sjogren's syndrome patients. Arthritis Rheum. (2003) 48(9):2573–2584.
   PubMedGoogle Scholar
• BORKAKOTI N: Matrix metalloprotease inhibitors: design from structure. Biochem. Soc. Trans. (2004) 32(1):17–20.
   PubMedGoogle Scholar
• MATTER H, SSCHUDOK M: Recent advances in the design of matrix metalloprotease inhibitors. Cuff. Opin. Drug Discov. Devel (2004) 7(4):513–535.
   PubMed Web of Science ®Google Scholar
• LEE M, MURPHY G: Matrix metalloproteinases at a glance. J. Cell Sci. (2004) 117:4015–4016.
   PubMed Web of Science ®Google Scholar
• NOEL A, MAILLARD C, ROCKS N et al: Membrane associated proteases and their inhibitors in tumour angiogenesis. Clin. PathoL (2004) 57:577–584.
   PubMed Web of Science ®Google Scholar
• MOHAMMED FF, SMOOKLER DS, KHOKHA R: Metalloproteinases, inflammation, and rheumatoid arthritis. Ann. Rheum. Dis. (2003) 62\(Supp1.11):43–47.
   Google Scholar
• GREEN WALD RA: Thirty-six years in the clinic without an MMP inhibitor: what hath collagenase wrought? Ann. NY Acad. Sci. (1999) 878:413–419.
   PubMed Web of Science ®Google Scholar
• HENROTIN Y, SANCHEZ C, REGINSTER JY: The inhibition of metalloproteinases to treat osteoarthritis: reality and new perspectives. Expert Opin. Ther. Patents (2002) 12(1):29–43.
   Web of Science ®Google Scholar
• HANDE K, WILDING G, RIPPLE G et al.: A Phase I study of AG3340, a matrix metalloprotease (MMP) inhibitor, in patients having advanced cancer. Ann. Oncol (1998) Suppl. 2:279.
   Google Scholar
• WILDING G, SMALL E, COLLIER M et al.: A Phase I pharmacokinetic evaluation of the matrix metalloprotease (MMP) inhibitor AG3340 in combination with mitoxantrone and prednisone in patients with advanced prostate cancer. Proc. Am. Soc. Clin. Oncol (1999) 18:1244.
   Google Scholar
• RUGO HS, BUDMAN D, VOGEL C et al.: Phase II study of the matrix metalloprotease inhibitor prinomastat in patients with progressive breast cancer. Proc. Am. Soc. Clin. Oncol (2001) 20:187.
   Google Scholar
• AHMANN FR, SAAD F, MERCIER R et al.: Interim results of a Phase III study of the matrix metalloprotease inhibitor prinomastat in patients having metastatic, hormone refractory prostate cancer (HRPC). Proc. Am. Soc. Clin. Oncol (2001) 20:692.
   Google Scholar
• SMYLIE M, MERCIER R, ABOULAFIA D et al.: Phase III study of the matrix metalloprotease (MMP) inhibitor prinomastat in patients having advanced non-small cell lung cancer (NSCLC). Proc. Am. Soc. Clin. Oncol (2001) 20:1226.
   Google Scholar
• WOJTOWICZ-PRAGA S, LOW J, MARSHALL J et al.: Phase I trail of a novel matrix metalloprotease inhibitor batimastat (BB-94) in patients with advanced cancer. Invest. New Drugs (1996) 14:193–202.
   PubMed Web of Science ®Google Scholar
• BEATTIE GJ, SMYTH JF: Phase I study of intraperitoneal metalloprotease inhibitor BB94 in patients with malignant ascites. Clin. Cancer. Res. (1998) 4:1899–1902.
   PubMed Web of Science ®Google Scholar
• NEMUNAITIS J, POOLE C, PRIMROSE J et al.: Combined analysis of the effects of the matrix metalloproteinase inhibitor marimastat on serum tumor markers in advanced cancer: selection of a biologically active and tolerable dose for longer-term studies. Clin. Cancer Res. (1998) 4:1101–1109.
   PubMed Web of Science ®Google Scholar
• ROSEMURGY A, HARRIS J, LANGLEBEN A et al.: Marimastat in patients with advanced pancreatic cancer: a dose-finding study. Am. J. Clin. Oncol (1999) 22:247–252.
   PubMed Web of Science ®Google Scholar
• RHODES DA, IHRKE G, REINICKE AT et al: The 52000 MW Ro/SS-A autoantigen in Sjogren's syndrome/systemic lupus erythematosus (Ro52) is an IFN-y inducible tripartite motif protein associated with membrane proximal structures. Immunology (2002) 106:246–256.
   PubMed Web of Science ®Google Scholar
• WU AJ, LAFRENIE RM, PARK C et al.: Modulation of MMP-2 (gelatinase A) and MMP-9 (gelatinase B) by IFN-y in human salivary gland cell line./ Cell. Phys. (1998) 171(2):117–124.
   Google Scholar
• AARONSON DS, HORVARTH CM: A road map for those who don't know JAK-STAT. Science (2002) 296(5573):1653–1655.
   PubMed Web of Science ®Google Scholar
• SKURKOVICH SV, KASPAROV A, NARBUT N et al.: Treatment of corneal transplant rejection in humans with anti-IFN-y antibodies. Am. J. Opthalmol (2002) 133(6):829–830.
   PubMed Web of Science ®Google Scholar
• SMOLLE M, KELLER C, PINGERRA G et al.: Clear hydro-gel, compared to ointment, provides improved eye comfort after brief surgery. Can. J. Anaesth. (2004) 51(2):126–129.
   PubMed Web of Science ®Google Scholar
• ARAGONA P, DI STEFANO G, FERRERI F et al.: Sodium hyaluronate eye drops of different osmolarity for the treatment of dry eye in Sjogren's syndrome patients. Br. J. Ophthalmol (2002) 86(8):879–884.
   PubMed Web of Science ®Google Scholar
• STIENFELD SD, DEMOLS P, SALMON I et al.: Infliximab in patients with primary Sjogren's syndrome: a pilot study. Arthritis Rheum. (2001) 44:2371–2375.
   PubMedGoogle Scholar
• STIENFELD SD, DEMOLS P, APPLEBOOM T: Infliximab in primary Sjogren's syndrome: one-year followup. Arthritis Rheum. (2002) 46 (12):3301–3303.
   PubMedGoogle Scholar
• MARTIN LS, MIGLIORE A, TODINO V et al.: Infliximab therapy in patients with secondary Sjogren's syndrome: functional evaluation. Clin. Exp. Rheumatol (2003) 21(3):412.
   Web of Science ®Google Scholar
• MARIETTE X, RAVAUD P, STEINFELD S et al.: Inefficacy of infliximab in primary Sjogren's syndrome: Results of the randomized, controlled trial of remicade in primary Sjogren's syndrome (TRIPSS). Arthritis Rheum. (2004) 50(4):1270–1276.
   PubMed Web of Science ®Google Scholar
• ZANDBELT MM, DE WILDE P, VAN DAMME P et al.: Etanercept in the treatment of patients with primary Sjogren's syndrome: a pilot study. J. Rheumatol (2004) 31(1):96–101.
   Google Scholar
• SANKAR V, BRENNAN MT, KOK MR et al.: Etanercept in Sjogren's syndrome: a twelve-week randomized, double-blind, placebo-controlled pilot clinical trial. Arthrtis Rheum. (2004) 50(7):2240–2245.
   PubMedGoogle Scholar
• SHIP JA, FOX PC, MICHALEK JE et ell.:Treatment of primary Sjogren's syndrome with low-dose natural human IFN-a administered by the oral mucosal route: a Phase II clinical trial. IFN Protocol Study Group. J. Interferon Cytokine Res. (1999) 19:943–951.
   Google Scholar
• SHIOZAWA S, TANAKA Y, SHIOZAWA K: Single-blinded controlled trial of low-dose oral IFN-a for the treatment of xerostomia in patients with Sjogren's syndrome./ Interferon Cytokine Res. (1998) 18:255–262.
   PubMed Web of Science ®Google Scholar
• CUMMINS MJ, PAPAS A, KAMMER GM et al.: Treatment of primary Sjogren's syndrome with low-dose human IFN-a administered by the oromucosal route: combined Phase III results. Arthritis Rheum. (2003) 49:585–593.
   PubMed Web of Science ®Google Scholar
• SILVERMAN GJ, WEISMAN S: Rituximab therapy and autoimmune disorders: prospect for anti-B cell therapy. Arthritis Rheum. (2003) 48:1484–1492.
   PubMed Web of Science ®Google Scholar
• SKURKOVICH B, SKURKOVICH S: Anti-IFN-y antibodies in the treatment of autoimmune disease. Curr. Opin. Molec. Ther. (2003) 5(1):52–57.
   PubMedGoogle Scholar
• KUNERT KS, TISDALE AS, STERN ME et al.: Analysis of topical cyclosporine treatment of patients with dry eye syndrome: effect on conjuctival lymphocytes. Arch. Ophthalmol (2000) 118(1):1489–1496.
   PubMedGoogle Scholar
• TAUBER J, DAVITT WF, BOKOSKY JE et al.: Double-masked, placebo-controlled safety and efficacy trial of diquafosol tetrasodium (11\15365) ophthalmic solution for the treatment of dry eye. Cornea (2004) 23(8):784–792.
   PubMed Web of Science ®Google Scholar
• NELL B, WAIDE I, BILLICH A et al.: The effect of topical pimecrolimus on keratoconjuctivitis sicca and chronic superficial keratitis in dogs: results from an exploratory study. Vet Ophthalmol (2005) 8(1):39–46.
   PubMed Web of Science ®Google Scholar
• SENGOKU T, SAKUMA S, SATOH S et al.: Effect of FK506 eye drops on late and delayed-type responses in ocular allergy models. Clin. Exp. Allergy (2003) 33(11):556–560.
   Web of Science ®Google Scholar
• O'BRIEN PD, COLLUM LM: Dry eye: diagnosis and current treatment strategies. Curr. Allergy Asthma Rep. (2004) 4(4):314–319.
   PubMed Web of Science ®Google Scholar